Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about EGR: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| Kupffer Cell Enhancers | regulates | mechanism | 0.90 |
| Kupffer cell enhancers | regulates | pathway | 0.80 |
| KUPFFER_CELLS | regulates | cell_type | 0.64 |
| Source | Relation | Type | Str |
|---|---|---|---|
| No incoming edges | |||
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Closed-loop tACS targeting entorhinal cortex layer II SST in | 0.625 | Alzheimer's disease | Circuit-level neural dynamics in neurode |
| Integrated Biomarker Panel for Therapeutic Window Identifica | 0.615 | neurodegeneration | What are the precise temporal dynamics o |
| Selective APOE4 Degradation via Proteolysis Targeting Chimer | 0.595 | neurodegeneration | APOE4 structural biology and therapeutic |
| SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysoso | 0.542 | neurodegeneration | What molecular mechanisms link elevated |
| Granzyme B Inhibition with Serpina3n to Preserve Axonal Inte | 0.514 | neuroimmunology | Do CXCL10-recruited CD8+ T cells provide |
| Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention fo | 0.465 | neurodegeneration | CRISPR-based therapeutic approaches for |
| Neuronal Integrated Stress Response Modulation | 0.452 | neurodegeneration | Cell type vulnerability in Alzheimer's D |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-16 | 7 hypotheses Top: 0.780
neuroinflammation | 2026-04-14 | 2 hypotheses Top: 0.499
neuroinflammation | 2026-04-13 | 0 hypotheses
neurodegeneration | 2026-04-11 | 0 hypotheses
neuroinflammation | 2026-04-08 | 0 hypotheses
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Why Does Amyloid Removal Only Slow Decline 27%? — Mechanistic investig | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
| Down Syndrome Alzheimer's Disease: Mechanisms and Therapeutic Timing | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| s:** - Biochemical binding assays measuring PROTAC selectivity for APO | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685] | Litvinchuk A, Suh JH, Guo JL, Lin K, Dav | Neuron | 2024 | 1 |
| The cell biology of APOE in the brain. [PMID:37805344] | Windham IA, Cohen S | Trends Cell Biol | 2024 | 1 |
| The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317] | Maxine R Nelson, Peng Liu, Ayushi Agrawa | Nature neuroscience | 2023 | 1 |
| APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] | Serrano-Pozo A, Das S, Hyman BT | Lancet Neurol | 2021 | 1 |
| Lysosome-targeting chimaeras for degradation of extracellular proteins. [PMID:32728216] | Banik SM, Pedram K, Wisnovsky S, Ahn G, | Nature | 2020 | 1 |
| Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] | Long JM, Holtzman DM | Cell | 2019 | 1 |
| Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. [PMID:31367008] | Yamazaki Y, Zhao N, Caulfield TR, Liu CC | Nat Rev Neurol | 2019 | 1 |
| Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188] | Cetindag AC, Schipke CG, Esselmann H, Kr | The journal of prevention of A | 2026 | 0 |
| Perioperative polygenic and APOE-based genetic risk assessment for neurocognitiv [PMID:40562635] | Thedim M, Hu J, Maher M, Wiener-Kronish | Br J Anaesth | 2026 | 0 |
| Increased genetic protection against Alzheimer's disease in centenarians. [PMID:40615639] | Bae H, Song Z, Ali A, Sasaki T, Tesi N e | Geroscience | 2026 | 0 |
| Integrative machine learning approach to risk prediction for dementia and Alzhei [PMID:40864401] | Stern A, Linial M | Geroscience | 2026 | 0 |
| Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasi [PMID:40886963] | Zhu L, Du L, Wu J, Ding D, Wang J et al. | J Invest Dermatol | 2026 | 0 |
| Restoration of p53 mRNA combined with BRD4 silencing by brain targeted nanocapsu [PMID:41101204] | Sang Y, Cao Y, Li S, Quan Y, Wang S et a | Biomaterials | 2026 | 0 |
| Targeting KAT8 alleviates vascular senescence by modulating the INHBA/TGF-β path [PMID:41445196] | Lin Z, Xiong J, Zhang F, Zhang H, Zhu M | Mol Ther | 2026 | 0 |
| Menopause, cognition, and Alzheimer's disease risk. [PMID:41531227] | Samudra N, Vemuri M, Weitlauf J | Curr Opin Obstet Gynecol | 2026 | 0 |
| ApoE-directed CpG nano-immunoadjuvant ameliorates Alzheimer's-like pathology in [PMID:41651379] | Huang X, Sun YY, Qin YR, Chen H, Pan TT | J Control Release | 2026 | 0 |
| Albofungin vesicle nanobombs trigger lysosomal disruption for self-enhanced pyro [PMID:41679437] | Chen C, Tan S, Zhu X, Song Z, Xing Y et | J Control Release | 2026 | 0 |
| Covalent Bond Locking in Semiconducting Oligomers Boosts Ultrabright NIR-II Lumi [PMID:41757652] | Li X, Gan H, Zhang C, Gao Y, Zhang J et | Angew Chem Int Ed Engl | 2026 | 0 |
| Inflammation-related miR-155-5p as an APOE ε4-modulated biomarker for amyloid pa [PMID:41930593] | Yoshida K, Saito N, Takahashi R, Ando S, | J Alzheimers Dis | 2026 | 0 |
| UBE2I Alleviates Pyroptosis in Coronary Heart Disease by Promoting the SUMOylati [PMID:41930933] | Ding SK | Immunol Invest | 2026 | 0 |